文献速递造血干细胞移植与细胞治疗血栓与止血

核因子红系2相关因子2激动剂叔丁基对苯二酚改善异基因造血干细胞移植后持续性孤立性血小板减少症患者的骨髓间充质干细胞功能

The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation.
PubMed 文献 · Br J Haematol · 2022-12-04

本病例对照研究探讨核因子红系2相关因子2(NRF2)与异基因造血干细胞移植(allo-HSCT)后持续性孤立性血小板减少症(PT)的关联,并体外评估NRF2激动剂叔丁基对苯二酚(TBHQ)对PT患者骨髓间充质干细胞(BM MSC)的作用。发现PT患者BM MSC活性氧升高、NRF2表达降低,低NRF2表达是原发性PT的独立危险因素(p=0.032,OR 0.868,95%CI 0.764-0.988);TBHQ体外改善BM MSC数量与功能并恢复其对巨核细胞生成的支撑。

要点

  • PT患者BM MSC活性氧水平升高且NRF2表达降低。
  • 低NRF2表达是原发性PT的独立危险因素(p=0.032,OR 0.868,95%CI 0.764-0.988)。
  • TBHQ体外改善PT患者BM MSC数量与功能,并恢复其对巨核细胞生成的支撑。

核心结论

  • 结果提示人BM MSC中NRF2下调可能参与allo-HSCT后PT的发病机制,且BM MSC损伤可在体外被NRF2激动剂改善。
  • 作者认为,尽管需要进一步验证,NRF2激动剂可能是allo-HSCT后PT患者的潜在治疗方法。

研究设计与样本

  • 病例对照研究,研究对象为allo-HSCT后PT患者,评估NRF2与PT的关联并在体外用NRF2激动剂TBHQ处理PT患者的BM MSC。

主要发现

  • PT患者BM MSC表现出活性氧水平升高和NRF2表达降低。
  • 多因素分析显示低NRF2表达是原发性PT的独立危险因素(p=0.032,OR 0.868,95%CI 0.764-0.988)。
  • 体外TBHQ处理通过下调活性氧水平改善PT患者BM MSC的数量和功能,并恢复受损的BM MSC对巨核细胞生成的支撑。

临床怎么用

  • 作者认为NRF2激动剂可能是allo-HSCT后PT患者的潜在治疗方法,但原文同时指出需要进一步验证。

局限性

  • 原文指出需要进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prolonged isolated thrombocytopenia (PT) is a life-threatening comorbidity associated with allogeneic haematopoietic stem cell transplantation (allo-HSCT). Our previous study indicated that dysfunctional bone marrow mesenchymal stromal cells (BM MSCs) played a role in PT pathogenesis and that reactive oxygen species (ROS) accumulation was related to BM MSC senescence and apoptosis. However, the mechanism of the increase in ROS levels in the BM MSCs of PT patients is unknown. In the current case-control study, we investigated whether nuclear factor erythroid 2-related factor 2 (NRF2), which is a central regulator of the cellular anti-oxidant response that can clear ROS in human BM MSCs, was associated with PT after allo-HSCT. We evaluated whether an NRF2 agonist (tert-butylhydroquinone, TBHQ) could enhance BM MSCs from PT patients in vitro. We found that BM MSCs from PT patients exhibited increased ROS levels and reduced NRF2 expression. Multivariate analysis showed that low NRF2 expression was an independent risk factor for primary PT [p = 0.032, Odds ratio (OR) 0.868, 95% confidence interval (CI) 0.764-0.988]. In-vitro treatment with TBHQ improved the quantity and function of BM MSCs from PT patients by downregulating ROS levels and rescued the impaired BM MSC support of megakaryocytopoiesis. In conclusion, these results suggested that NRF2 downregulation in human BM MSCs might be involved in the pathogenesis of PT after allo-HSCT and that BM MSC impairment could be improved by NRF2 agonist in vitro. Although further validation is needed, our data indicate that NRF2 agonists might be a potential therapeutic approach for PT patients after allo-HSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Luo XY, Kong Y, Lv M, et al. The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2022. PMID: 36464324. doi:10.1111/bjh.18585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。